Botanix Pharmaceuticals

Unlocking the potential of synthetic cannabinoids

Pharmaceutical company leveraging the unique properties of synthetic cannabinoids with its Permetrex™ technology

Promising R&D, with a rapidly advancing pipeline of dermatology and antimicrobial products

World-class team with extensive cannabinoid drug development and commercialisation expertise

Evidence, first

Botanix Pharmaceuticals is a clinical stage synthetic cannabinoid pharmaceutical company with a targeted pipeline of dermatology and antimicrobial products. We have attracted a world-class team and significant capital to support the progression of our products. We are moving quickly, but never at the expense of our rigorous commitment to ethical research and development (R&D) and the highest clinical standards mandated by the US Food and Drug Administration (FDA). Our goal is to unlock the true potential of synthetic cannabinoids for people around the world, with an evidence-first approach.

Check out our latest news

WHO warns overuse of antibiotics for Covid-19 will cause more deaths

The increased use of antibiotics to combat the Covid-19 pandemic…

Path To Profitability

According to the industry analysts covering BOT, breakeven is…

Is Cannabis Space Offering a Lucrative Investment Opportunity Amid Coronavirus Outbreak?

The legal cannabis market in Australia is set to boom, and cannabis is…

Botanix Pharmaceuticals receives FDA grant for antibacterial product BTX 1801

Amid the difficulties created by the COVID-19 pandemic, synthetic…

Botanix reshuffles business priorities

Botanix Pharmaceuticals Limited (ASX: BOT) today provided…

Botanix signs a supply agreement with Purisys

Botanix Pharmaceuticals has entered into a supply agreement…

Pharma giants to unveil major $1 billion venture to push novel antibiotics

Amid escalating concerns over antibiotic resistance, several…

Prepare for Lift-off – Botanix raises $40 million and strengthens leadership team

Botanix Pharmaceuticals Limited (ASX:BOT)—a clinical stage…

Invest in innovation

Botanix Pharmaceuticals offers a compelling opportunity for investors who are interested in capitalising on the clinical potential of synthetic cannabinoids. Our clinical trials to date have highlighted the unique mechanism of action which drives synthetic cannabidiol to produce anti-inflammatory and antimicrobial effects. We are leveraging this evidence to inform the development of new pharmaceutical products, targeting some of the most underserved and lucrative segments of the global healthcare market. Already, we have one of the most advanced clinical pipelines for synthetic cannabinoids in the world.

New treatments, in demand

Botanix has generated strong scientific support for the anti-inflammatory and antimicrobial mechanisms of action of synthetic cannabinoids with application in the development of novel dermatology and bacteria fighting applications.

There have been no new chemical entities (NCE’s) in topical drugs approved for acne in more than two decades and resistance to available antibiotics remains a significant global issue, with no new classes of antibiotics approved in more than three decades. When bacteria survive exposure to antibiotics that would normally eliminate them, these surviving bacteria grow and spread resistance, leading to the emergence of ‘superbugs’. New treatments in dermatology and anti-microbials are needed now.

Botanix periodically runs clinical studies in Australia, New Zealand the USA. Share your details if you would like to learn more.

Sign up to receive our latest news.

Processing...
Thank you! Your subscription has been confirmed. You'll hear from us soon.
ErrorHere